Shield Therapeutics (LON:STX) Receives Buy Rating from Peel Hunt

Shield Therapeutics (LON:STX)‘s stock had its “buy” rating restated by research analysts at Peel Hunt in a report released on Friday, Marketbeat Ratings reports. They presently have a GBX 15 target price on the stock. Peel Hunt’s target price points to a potential upside of 116.61% from the company’s previous close.

Shield Therapeutics Stock Performance

Shares of Shield Therapeutics stock traded up GBX 0.18 on Friday, reaching GBX 6.93. 2,286,293 shares of the company traded hands, compared to its average volume of 2,729,643. The company has a 50 day moving average of GBX 7.54 and a 200 day moving average of GBX 4.91. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. Shield Therapeutics has a 52 week low of GBX 2.10 and a 52 week high of GBX 9.10. The firm has a market capitalization of £73.53 million, a PE ratio of -3.46 and a beta of 1.42.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.